Adverse reactions to biologic agents: Focus on autoimmune disease therapies

被引:46
作者
Lee, SJ [1 ]
Kavanaugh, A [1 ]
机构
[1] Univ Calif San Diego, Div Rheumatol Allergy & Immunol, La Jolla, CA 92093 USA
关键词
Rheumatoid arthritis; biologic agents; adverse reactions; monoclonal antibodies;
D O I
10.1016/j.jaci.2005.03.028
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
In recent years, a growing number of biologic agents have become available for the treatment of various autoimmune, neoplastic, cardiovascular, infectious, allergic, and other conditions. Their introduction has resulted in marked clinical improvements for many patients. Nevertheless, a variety of adverse reactions have been observed with these agents. Because many biologic agents affect key components of sundry physiologic processes, a number of important adverse reactions might be considered mechanism based. Other adverse reactions relate to the agent rather than the target, including hypersensitivity reactions. As a means of exploring the spectrum of potential adverse effects related to biologic agents and their mechanisms, this review will focus on the experience to date with biologic agents used for the treatment of autoimmune disorders. An understanding of the spectrum and types of reactions possible with biologic agents, as well as the mechanisms underlying such reactions, will help clinicians use them optimally.
引用
收藏
页码:900 / 905
页数:6
相关论文
共 40 条
[1]   CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris [J].
Abrams, JR ;
Lebwohl, MG ;
Guzzo, CA ;
Jegasothy, BV ;
Goldfarb, MT ;
Goffe, BS ;
Menter, A ;
Lowe, NJ ;
Krueger, G ;
Brown, MJ ;
Weiner, RS ;
Birkhofer, MJ ;
Warner, GL ;
Berry, KK ;
Linsley, PS ;
Krueger, JG ;
Ochs, HD ;
Kelley, SL ;
Kang, SW .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (09) :1243-1252
[2]   Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease [J].
Baert, F ;
Noman, M ;
Vermeire, S ;
Van Assche, G ;
D'Haens, G ;
Carbonez, A ;
Rutgeerts, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (07) :601-608
[3]  
Benini J, 1999, J PATHOL, V189, P127, DOI 10.1002/(SICI)1096-9896(199909)189:1<127::AID-PATH398>3.0.CO
[4]  
2-S
[5]   Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments [J].
Bieber, J ;
Kavanaugh, A .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2004, 30 (02) :257-+
[6]   Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial [J].
Chung, ES ;
Packer, M ;
Lo, KH ;
Fasanmade, AA ;
Willerson, JT .
CIRCULATION, 2003, 107 (25) :3133-3140
[7]   The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients [J].
Colombel, JF ;
Loftus, EV ;
Tremaine, WJ ;
Egan, LJ ;
Harmsen, WS ;
Schleck, CD ;
Zinsmeister, AR ;
Sandborn, WJ .
GASTROENTEROLOGY, 2004, 126 (01) :19-31
[8]   Anti-TNF-α-induced systemic lupus syndrome [J].
Debandt, M ;
Vittecoq, O ;
Descamps, V ;
Le Loët, X ;
Meyer, O .
CLINICAL RHEUMATOLOGY, 2003, 22 (01) :56-61
[9]   Rituximab-induced vasculitis [J].
Dereure, O ;
Navarro, R ;
Rossi, JF ;
Guilhou, JJ .
DERMATOLOGY, 2001, 203 (01) :83-84
[10]  
Fleishmann RM, 2002, CLIN EXP RHEUMATOL, V20, pS35